CN118119719A - 使用her3抗原结合分子治疗和预防癌症 - Google Patents
使用her3抗原结合分子治疗和预防癌症 Download PDFInfo
- Publication number
- CN118119719A CN118119719A CN202280069429.9A CN202280069429A CN118119719A CN 118119719 A CN118119719 A CN 118119719A CN 202280069429 A CN202280069429 A CN 202280069429A CN 118119719 A CN118119719 A CN 118119719A
- Authority
- CN
- China
- Prior art keywords
- cancer
- mutation
- amino acid
- her3
- binding molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163232883P | 2021-08-13 | 2021-08-13 | |
| US63/232,883 | 2021-08-13 | ||
| PCT/EP2022/072674 WO2023017151A1 (en) | 2021-08-13 | 2022-08-12 | Treatment and prevention of cancer using her3 antigen-binding molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118119719A true CN118119719A (zh) | 2024-05-31 |
Family
ID=83228993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280069429.9A Pending CN118119719A (zh) | 2021-08-13 | 2022-08-12 | 使用her3抗原结合分子治疗和预防癌症 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250136712A1 (https=) |
| EP (1) | EP4384640A1 (https=) |
| JP (1) | JP2024529141A (https=) |
| KR (1) | KR20240045281A (https=) |
| CN (1) | CN118119719A (https=) |
| WO (1) | WO2023017151A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4687972A1 (en) | 2023-04-06 | 2026-02-11 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using her3 antigen-binding molecules |
| WO2025056781A1 (en) * | 2023-09-15 | 2025-03-20 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using her3-binding molecules |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140222443A1 (en) * | 2011-06-07 | 2014-08-07 | Kathleen Danenberg | Molecular profiling for cancer |
| JP2020533269A (ja) * | 2016-12-14 | 2020-11-19 | デベロップメント センター フォー バイオテクノロジー | 抗体−薬物複合体およびその使用 |
| WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
| GB201913079D0 (en) | 2019-09-11 | 2019-10-23 | Hummingbird Bioscience Holdings Pte Ltd | Treatment and prevention of cancer using her3 antigen-binding molecules |
-
2022
- 2022-08-12 US US18/683,155 patent/US20250136712A1/en active Pending
- 2022-08-12 CN CN202280069429.9A patent/CN118119719A/zh active Pending
- 2022-08-12 EP EP22765487.8A patent/EP4384640A1/en active Pending
- 2022-08-12 KR KR1020247007953A patent/KR20240045281A/ko active Pending
- 2022-08-12 WO PCT/EP2022/072674 patent/WO2023017151A1/en not_active Ceased
- 2022-08-12 JP JP2024508570A patent/JP2024529141A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023017151A9 (en) | 2024-06-06 |
| WO2023017151A1 (en) | 2023-02-16 |
| EP4384640A1 (en) | 2024-06-19 |
| JP2024529141A (ja) | 2024-08-01 |
| US20250136712A1 (en) | 2025-05-01 |
| KR20240045281A (ko) | 2024-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023103258A (ja) | がんの治療法及び診断法 | |
| JP2022172083A (ja) | 癌のための治療方法及び診断方法 | |
| JP6449308B2 (ja) | がんバイオマーカー及びその使用 | |
| TW201819640A (zh) | 癌症之治療性及診斷性方法 | |
| KR20130103734A (ko) | 바이오마커 및 치료 방법 | |
| JP2018534927A (ja) | Ｉｃｏｓ発現を決定する遺伝子シグネチャー | |
| JP2016508028A (ja) | Ｐｄ−ｌ１阻害剤併用療法を必要とする患者の同定 | |
| CN112912403A (zh) | 治疗肿瘤的方法 | |
| US20240310266A1 (en) | Biomarkers for cancer and methods of use thereof | |
| CN112292151B (zh) | 抗pd-1抗体在制备治疗实体瘤的药物中的用途 | |
| US20240101707A1 (en) | A method of preventing, alleviating or treating a tumor | |
| EP3898675A1 (en) | Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome | |
| CN113891748A (zh) | 治疗肿瘤的方法 | |
| US20250136712A1 (en) | Treatment and prevention of cancer using her3 antigen-binding molecules | |
| CN114728070A (zh) | 用于癌症疗法的复合生物标记物 | |
| US20180171027A1 (en) | Biomarkers Related to Treatment of Cancer with HER3 and EGFR Inhibitors | |
| WO2021160151A1 (zh) | 抗pd-1抗体在治疗肿瘤中的用途 | |
| US20230392210A1 (en) | Methods and compositions for cancer immunotherapy | |
| JP2023520515A (ja) | がんに対する治療方法及び診断方法 | |
| EP4687972A1 (en) | Treatment and prevention of cancer using her3 antigen-binding molecules | |
| JP2026513904A (ja) | Ｈｅｒ３抗原結合分子を使用する、がんの処置および予防 | |
| WO2025056781A1 (en) | Treatment and prevention of cancer using her3-binding molecules | |
| WO2024254596A9 (en) | Compositions and methods for detection of aberrant cdk5 expression | |
| JP2025541137A (ja) | Ｄｌｌ３発現癌を治療するための方法 | |
| WO2020181080A1 (en) | Biomarkers for treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |